Wang Wujun, Xie Shengfang, Yuan Dongping, He Dandan, Fang Liming, Ge Fengfeng
Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Nanjing University of Chinese Medicine, Nanjing, China.
Front Oncol. 2022 Jan 28;11:773236. doi: 10.3389/fonc.2021.773236. eCollection 2021.
Renal cancer (RC) is one of the most common malignant tumors of the urinary system, and molecular targets for the specific diagnosis and treatment of RC have been widely explored. The purpose of this study was to systematically analyze circular RNAs (circRNAs), which may serve as novel tumor markers in terms of the diagnosis, prognosis and clinicopathological characteristics of RC.
PubMed and Web of Science were systematically searched for literature as up to July 30, 2021. All included studies were evaluated by the evaluation system, and the results were satisfactory. Hazard ratios (HRs) and odds ratios (ORs) were used to assess the association of circRNAs with diagnostic and clinicopathological indicators. The sensitivity (SEN), specificity (SPE), positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the summary receiver operating characteristic curve (AUC) were combined to evaluate the diagnostic performance of circRNAs in RC.
We included 22 studies that met the criteria, including 18 that were prognostic, 4 that were diagnostic, and 12 that were clinicopathologically relevant. In terms of prognosis, we found that upregulated circRNAs were positively associated with poor overall survival in patients with RC (HR=1.63, 95% CI=1.43-1.85). In terms of diagnosis, the combined SEN, SPE and AUC of circRNAs in the diagnosis of RC were 0.82, 0.84 and 0.89 (0.86-0.91), respectively. In terms of clinicopathological features, upregulated circRNAs were associated with the Fuhrman grade (OR=0.641, 95% CI=0.471-0.873), T stage (OR=0.236, 95% CI=0.141-0.396), TNM stage (OR=0.225, 95% CI=0.158-0.321) and lymphatic metastasis (OR=0.329, 95% CI=0.193-0.560).
Our meta-analysis confirms that circRNAs may be candidate biomarkers for the diagnosis, prognosis, and clinicopathological indicators of RC.
肾癌（RC）是泌尿系统最常见的恶性肿瘤之一，针对RC特异性诊断和治疗的分子靶点已得到广泛探索。本研究的目的是系统分析环状RNA（circRNAs），其在RC的诊断、预后及临床病理特征方面可能作为新型肿瘤标志物。
系统检索PubMed和Web of Science截至2021年7月30日的文献。所有纳入研究均采用评估系统进行评估，结果令人满意。采用风险比（HRs）和比值比（ORs）评估circRNAs与诊断及临床病理指标的关联。结合敏感度（SEN）、特异度（SPE）、阳性似然比、阴性似然比、诊断比值比及汇总受试者工作特征曲线下面积（AUC）评估circRNAs在RC中的诊断性能。
我们纳入了22项符合标准的研究，其中18项为预后相关研究，4项为诊断相关研究，12项为临床病理相关研究。在预后方面，我们发现上调的circRNAs与RC患者较差的总生存期呈正相关（HR = 1.
